Psoriasis

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…

This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve …

This completed Phase 3 trial tested the drug guselkumab (Tremfya) in 211 people with skin of color who have moderate-to-severe plaque psoriasis or scalp psoriasis. Participants received either guselkumab or a placebo injection. The study measured how well the drug cleared skin le…

This study is testing how the drug guselkumab affects the immune system in people with two types of psoriasis: plaque and guttate. Twenty-five adults will receive guselkumab injections over 44 weeks. Researchers will measure changes in immune cells in the skin to understand how t…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis treatment (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for…

This study tested a new oral medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. 227 adults who completed a previous 16-week study continued treatment for up to 36 more weeks. The goal was to see how well the drug kept skin clear over time.

This study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…

This study tested two doses of bimekizumab, a drug that targets inflammation, in 41 adolescents aged 12 to 17 with moderate to severe plaque psoriasis. The main goals were to measure how the drug behaves in the body and to check its safety. Researchers also looked at how well it …

This phase 2 trial tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had cardiometabolic risks (like obesity and high cholesterol). The goal was to see if orticumab could safely reduce skin plaques and inflammation linked to heart disease. Par…

This phase 3 trial tested whether a new biologic called CMAB015 works as well as secukinumab (Cosentyx) for moderate-to-severe plaque psoriasis. 336 adults received either drug for up to 48 weeks. The main goal was to see if at least 75% of skin symptoms improved by week 12. The …

This study tested special clothing made with Lumiton yarn that captures sunlight and turns it into red and near-infrared light, aiming to improve skin conditions like psoriasis, alopecia areata, and polymorphous light eruption. Eighteen adults with mild-to-severe forms of these c…

This study tested an oral tablet called JNJ-77242113 in 90 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive the drug or a placebo for 16 weeks. The main goal was to see if the drug could improve psoriasis symptoms by at least 75% com…

This completed Phase 3 trial tested whether the experimental drug zasocitinib works better than the approved drug deucravacitinib for moderate-to-severe plaque psoriasis. Over 600 participants took one tablet and one capsule daily for 16 weeks. The main goal was to see how many a…

This completed phase 3 trial tested the drug guselkumab against a placebo in 338 adults with moderate plaque psoriasis covering only 2-15% of their body but including special sites like the scalp, face, or genitals. The goal was to see if guselkumab could clear or nearly clear ps…

This study tracked over 2,300 adults in Korea who were prescribed Skyrizi (risankizumab) for moderate to severe plaque psoriasis or psoriatic arthritis. Researchers monitored side effects and symptom changes for 52 weeks during routine doctor visits. The goal was to confirm the d…

This study tested Daxxin Psoriasis Shampoo in 41 adults with moderate scalp psoriasis. Participants used the shampoo 3 to 7 times a week for 6 weeks. The goal was to see if it reduced scalp redness, thickness, and scaling, and improved quality of life. Results showed most people …

This study tested whether a higher dose of the drug brodalumab works better than the standard dose for people with moderate-to-severe plaque psoriasis who weigh at least 120 kg. The trial involved 385 adults and lasted 52 weeks. The main goal was to see if more patients on the hi…

This study looked at 781 adults with moderate-to-severe plaque psoriasis and metabolic syndrome (a cluster of conditions like high blood pressure and obesity). Researchers wanted to see if adding a lifestyle intervention (diet and exercise) to the drug Secukinumab (Cosentyx) impr…

This study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not improved with other similar treatments. The drug works by blocking certain inflammatory substances in the body to reduce skin redness, scaling, and thickness. The main go…

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…

This phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …

This study compares two already-approved drugs, risankizumab (injection) and deucravacitinib (pill), for adults with moderate plaque psoriasis. About 393 participants who haven't used biologics before will receive one of the treatments for up to 44 weeks. The goal is to see which…

This Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukin…

This Phase 3 trial tested netakimab, a biologic drug given as a shot, against a placebo in 202 Chinese adults with moderate-to-severe plaque psoriasis. The main goal was to see if netakimab could improve skin symptoms by at least 75% (PASI75) or achieve clear/almost clear skin (s…

This study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then…

This study looked at the long-term safety and tolerability of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received bimekizumab injections over several years. The main goal was to track side effects and see …

This study tested a new daily medicine called ESK-001 in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces psoriasis severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the medicine for 24 weeks…

This study tested whether a new daily pill, ESK-001, can safely reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took either ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers me…

This study tested a new ointment (LEO 90100) against a standard one (Daivobet) for stable plaque psoriasis in 604 Chinese adults. Participants applied the treatment for 4 weeks. The goal was to see if the new ointment could clear or nearly clear psoriasis patches better than the …

This Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizu…

This study tested whether psoriasis patients who are stable on biologic drugs (IL17 or IL23 inhibitors) can safely reduce their dose without their skin condition getting worse. Researchers enrolled 244 adults with plaque psoriasis who had been on a normal dose for at least 6 mont…

This Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The ma…

This study looked at whether QLETLI, a biosimilar of adalimumab, is safe and effective for children and teens aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see how much their psoriasis symptoms improved, mea…

This observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to…

This study tested the drug risankizumab (Skyrizi) in 214 adults with moderate to severe genital or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks, then all received the drug. The goal was to see if it could clear or nearly clear the skin in these…

This study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could clear at least 75% of skin symptoms after 16 weeks compared to a placebo. Participants had psoriasis for at least 6 mont…

This early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses …

This study tested whether adding metformin, a common diabetes drug, to cyclosporine works better for psoriasis than cyclosporine alone. Thirty-two adults with moderate to severe psoriasis took part. Researchers measured skin improvement, body surface area affected, and quality of…

This study tested whether people with moderate-to-severe plaque psoriasis who achieve complete skin clearance after 20 weeks of guselkumab (Tremfya) can maintain that control with injections every 16 weeks instead of every 8 weeks. About 880 participants were enrolled, and the ma…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…

This study tested a gel called SGX302, which is activated by visible light, on 15 people with mild-to-moderate plaque psoriasis. The goal was to see if it could clear or nearly clear skin lesions over 18 weeks. The treatment is applied to the skin and then exposed to light, aimin…

This study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement…

This study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and mea…

This study looked at the long-term safety and effects of the drug apremilast in 160 children aged 6 to 17 with moderate to severe plaque psoriasis. Participants who had already completed one year of treatment could continue taking the drug for up to 208 weeks (about 4 years). The…

This Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, mea…

This study tested whether a generic tapinarof cream works as well as the brand-name VTAMA® cream for adults with plaque psoriasis. 560 participants used either the generic cream, the brand-name cream, or a placebo for 12 weeks. The goal was to see if the generic version is equall…

This phase 2 clinical trial tested an experimental oral drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to one of three doses of D-2570 or a placebo for 12 weeks. The main goal was to see how many people achieved at l…

This small study tested whether a short course of HIV drugs (emtricitabine and tenofovir) could reduce inflammation in people with plaque psoriasis. Only 8 people took part, and the main goal was to see changes in certain markers in skin biopsies. The study is complete, but resul…

This study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…

This large study looked at whether taking daily vitamin D or fish oil supplements could lower the risk of developing autoimmune diseases (like rheumatoid arthritis), reduce signs of inflammation in the blood, and ease chronic knee pain. Over 25,000 adults without prior cancer or …

This study looked at whether tildrakizumab, a drug already approved for psoriasis, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults took the drug for 6 months, and researchers measured heart function using special scans. The goal was to s…

This completed pilot study tested whether filtering inflammatory molecules from the blood using a device called Efferon CT can help people with severe psoriasis. Sixty adults with moderate to severe plaque psoriasis received the treatment, which involves circulating blood through…

This phase 2 trial tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could significantly reduce psoriasis skin symptoms (measu…

This study tested an experimental oral drug called TAK-279 in 1,108 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, a placebo, or an approved psoriasis drug (apremilast) for up to 69 weeks. The main goal was to see if TAK-279 could clear or …

This phase 2a study tested an experimental drug called ASKP1240 in 60 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo intravenously. The main goals were to check safety, how the drug moves through the body, and early signs of ef…

This completed study followed 2759 adults with moderate to severe plaque psoriasis to see how well risankizumab works compared to other commonly used biologic drugs. Researchers measured skin clearance and how long patients stayed on treatment. The goal was to understand real-wor…

This study tested a new oral medication, SAR441566, in 221 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75%. Results will help det…

This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The main goal was to see if more people achieved clear or almost clear scalp skin after 16 weeks of treatment. This is a disease-control study, mea…

This Phase 3 study tested an experimental oral drug called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved treatment (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 reduces skin p…

This pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better reduce certain skin immune cells (resident memory T cells) and improve skin clearance. The study was complete…

This study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …

This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…

This study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …

This study tested a drug called spesolimab in 59 people with palmoplantar pustulosis (PPP), a painful skin condition causing pustules and plaques on the palms and soles. Participants received either low or high doses of spesolimab or a placebo for 12 weeks. The goal was to see if…

This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.

This study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The drug aims to quickly clear skin pustules. Results showed that more patients receiving spesolimab had no visible pustules after one wee…

This study tested an oral drug called upadacitinib (RINVOQ) against a placebo and an injected drug (adalimumab/Humira) in 1705 people with active psoriatic arthritis who had not responded well to standard non-biologic treatments. The goal was to see if upadacitinib reduces joint …

This study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was…

This phase 2 trial tested a monthly injection called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a chronic skin condition causing painful, pus-filled blisters on the palms and soles. The study compared the drug to a placebo to see if it could reduce the severi…

This phase 3 trial tested whether Bmab 1200, a biosimilar of the drug Stelara, works as well as Stelara for people with moderate to severe plaque psoriasis. 384 adults received either Bmab 1200 or Stelara over 40 weeks. The main goal was to see how much psoriasis symptoms improve…

This phase 3 study tested upadacitinib, an oral anti-inflammatory drug, in 642 adults with active psoriatic arthritis who had not responded well to at least one biologic treatment. Participants received either 15 mg or 30 mg of upadacitinib daily or a placebo. The main goal was t…

This study tested an experimental oral drug called LY4100511 (DC-853) in 222 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive different doses of the drug or a placebo. The main goal was to see how well the drug clears skin and whethe…

This completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world sett…

This study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…

This study tested whether an artificial intelligence tool called Legit Health Plus can help doctors track the severity of chronic skin conditions like acne, psoriasis, and eczema from a distance. 160 participants used a smartphone app for 6 months to take photos of their skin and…

This completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …

This study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…

This study tested a self-guided online program for people with psoriasis. 348 adults were split into two groups: one got the app plus their regular treatment, the other got regular treatment alone. The main goal was to see if the app improved quality of life over 12 months.

This study tests whether a daily skincare routine using Cetaphil cleansers and moisturizers can improve skin symptoms and quality of life for people with mild-to-severe plaque psoriasis. Participants apply the products to one side of their body while continuing their usual prescr…

This study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants received either the drug or a placebo. The main goal was to see if more people on the drug reported no or minimal impact of their s…

This early-phase study tested a medicated foam called ARQ-154 (roflumilast) in 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug enters the bloodstream and whether it is safe. Researchers monitored side effects and skin reactions ove…

This completed study tested a moisturizing medical device called RL3020-DP0364 (Dexeryl) in 40 adults with stable mild plaque psoriasis, dry skin, and itching. Participants applied the cream to their whole body (except head) for about a month. The main goal was to see if it reduc…

This study compared a new tapinarof cream to an already-approved one (Vtama®) for treating plaque psoriasis, a skin condition causing red, scaly patches. 575 adults with mild to moderate psoriasis used one of the creams or a placebo for a set time. The goal was to see if the new …

This study looked at how a prescription lotion (IDP-118) works in children aged 4 to 16 with moderate to severe plaque psoriasis. Researchers measured how much of the drug enters the bloodstream and whether it affects the body's stress hormone system (HPA axis). The goal was to c…

This study looked at whether intermittent fasting (eating only during certain hours) can reduce disease severity and improve quality of life for people with psoriasis and psoriatic arthritis. Sixty overweight adults were randomly assigned to either follow an intermittent fasting …

This Phase 3 study tested the drug tildrakizumab in 99 adults with moderate to severe nail psoriasis. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and reduced pain. The trial is complete, and results may help determine if t…

This study tested a cream made from plant compounds (total coumarins) in 88 adults with mild-to-moderate psoriasis. Participants applied the cream or a placebo for several weeks. The goal was to see if the cream safely reduces skin redness, scaling, and thickness better than a pl…

This study tested whether a smartphone-based cognitive behavioral therapy (CBT) program could help adults with psoriasis who also have depression symptoms. 30 participants used the app for 8 weeks with guidance from a coach. The goal was to see if people would engage with the pro…

This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days…

This early-stage study tested a new drug called CAN10, an antibody that blocks a protein involved in inflammation. Researchers gave single doses to 80 healthy adults and repeated doses to people with mild to moderate plaque psoriasis to see if it is safe and how the body processe…

This study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if it could safely clear skin patches and improve symptoms over 12 weeks. Researchers measured how much skin improved using standard psoriasis scores.

This study tested an experimental drug called SCD-044 in 263 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo to see if it could improve skin symptoms like redness and scaling. The main goal was to measure how many people achieve…

This early-phase study tested deucravacitinib, an oral drug, for treating nail psoriasis. The goal was to see if it improves nail appearance and symptoms. Only one person took part, and researchers measured changes in nail psoriasis severity over 48 weeks. Because it's so small, …

This study tested whether an 8-week ketogenic or Mediterranean diet could reduce inflammation in 26 adults with obesity, psoriasis, and psoriatic arthritis. Participants followed one of the two diets, and researchers measured skin severity (PASI score) and joint activity (DAPSA s…

This study tested a 12-week online program called Immune Strength for people with psoriasis or psoriatic arthritis. The program provided tips on stress, sleep, nutrition, and exercise, plus one-on-one email coaching from a wellness professional. Researchers wanted to see if this …

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either AX-158 or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to see if the drug is safe and tolerable, with some early che…

This study followed 291 adults with mild-to-moderate scalp psoriasis who were prescribed a cream containing calcipotriene and betamethasone (Wynzora®). Researchers measured how satisfied patients were with the treatment, its effect on quality of life, and how well it worked in re…

This early-stage trial tested a new oral drug called SAR441566 in 38 adults with mild to moderate psoriasis. Participants took the drug or a placebo twice daily for 4 weeks. The main goal was to check safety and tolerability, while also looking at changes in skin lesion severity.…

This study looked at whether people with mild-to-moderate psoriasis prefer using Wynzora cream over Enstilar foam. Thirty adults who had previously used Enstilar foam tried Wynzora cream for four weeks. Researchers used questionnaires to measure preference, treatment satisfaction…

This completed study looked at 386 adults with psoriasis to understand how skin inflammation might be linked to heart and blood vessel diseases. Participants had up to seven visits over four years, including blood tests, heart scans, and optional skin biopsies. The goal was to se…

This completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…

This study looked at how the drug adalimumab affects gene activity in the skin of people with chronic plaque psoriasis. Researchers compared skin samples from normal, non-lesional, and lesional areas before and after treatment. The goal was to understand the immune changes that h…

This study looked at 24 adults with moderate-to-severe plaque psoriasis to understand how a single injection of risankizumab (Skyrizi) changes immune cells in the skin. The goal was to learn why some patients stay clear of psoriasis for up to 66 weeks without further treatment. R…

This pilot study tested whether time-restricted feeding (eating all daily calories between 8am and 2pm, then fasting for 18 hours) could reduce inflammation in men with mild to moderate psoriasis. 27 participants (including healthy volunteers) stayed at the clinic for 4.5 days, w…

This pilot study tested a nurse-led educational program for people with psoriasis. Twenty-four participants received extra education sessions over six weeks, alongside standard care. The goal was to see if the program was feasible and could improve disease knowledge, self-managem…

This study looked at skin samples from 170 people with psoriasis, atopic dermatitis (eczema), or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn activity and related enzymes in both affected and unaffected skin. The goal w…

This completed study looked at 52 adults with plaque psoriasis who had been on biologic drugs for at least one year. Researchers used questionnaires to measure treatment satisfaction, quality of life, depression, and personality type. The goal was to find out which clinical and p…

This study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impacts of moderate-to-severe psoriasis. 154 adults starting the medication risankizumab filled out the 30-question survey over 28 weeks. The goal was to validate the tool …

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…

This study aimed to create and test a decision aid for people with psoriasis or psoriatic arthritis who are starting or switching treatments. Researchers worked with 37 patients and their doctors to design a tool that supports shared decision-making. The goal was to help patients…

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective secukinumab is in everyday medical practice. Researchers recorded side effects and how well the drug cleared skin symptoms. The goal was to gather real-world evidence, not…

This completed registry study in Japan looked at how doctors treat palmoplantar pustulosis (PPP), a skin condition causing pus-filled blisters on hands and feet. Researchers collected data from 276 patients' medical records and clinic visits to understand which treatments are use…

This study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to ident…

This completed study looked at skin samples from 40 people with psoriasis to understand how certain immune cells (CD4+ T cells) and a protein called S100A7 behave in psoriatic skin. Researchers used special staining techniques to measure these components. The goal was to learn mo…

This study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…

This study looked at fatigue in 33 adults with psoriatic arthritis or psoriasis. Researchers used questionnaires to measure tiredness and see how it relates to disease severity and treatments. The goal was to better understand fatigue and its impact on quality of life.

This study looked at how skin blood flow and nerve sensitivity differ in psoriasis plaques compared to healthy skin. Twenty adults with psoriasis on their back received mild electrical currents to deliver vasodilators (acetylcholine, sodium nitroprussiate, or plain water) into bo…

This study involved 20 adults with psoriasis to see how Hemay005 tablets affect the way the body processes another drug called midazolam. Researchers also checked for heart rhythm changes and measured inflammation markers. The goal was to gather safety and drug interaction data, …

This completed Phase 1 study tested how the psoriasis drug Hemay005 is processed by the body in people with mild or moderate kidney impairment compared to those with normal kidneys. 26 adults took a single dose, and researchers measured drug levels in the blood to see if kidney f…

This completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long the…

This study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…

This study followed 240 adults in Taiwan with moderate-to-severe plaque psoriasis to see how well risankizumab works compared to other biologics in real-world settings. Participants received their prescribed treatment and were monitored for about 2 years. The main goal was to mea…

This completed Phase 1 trial in 18 healthy women aged 18–40 tested whether taking the experimental psoriasis drug HS-10374 changes how the body absorbs and clears the birth control pill Yasmin. Participants took Yasmin alone and then again after a course of HS-10374. Researchers …

This study checked if newer psoriasis drugs (IL17/23 inhibitors) also improve artery stiffness, a sign of heart disease. Researchers followed 66 people with moderate-to-severe psoriasis for a year, measuring pulse wave velocity (PWV) and other markers. The goal was to see if thes…

This study tested whether digital photographs can reliably measure psoriasis severity compared to in-person exams. Thirty-four adults with plaque psoriasis had their skin assessed both ways. The goal was to see if remote scoring could be as accurate as face-to-face evaluation.

This completed study examined whether people with psoriasis have worse gum health and how it affects their daily lives. Researchers compared 226 adults with and without psoriasis through oral exams and questionnaires. The goal was to understand if the chronic skin condition also …

This completed study looked at 100 adults with moderate-to-severe psoriasis to see how two common biologic drugs, Secukinumab and Adalimumab, affect bone density. Researchers measured bone mineral density in the spine and hip over time. The goal was to understand if these treatme…